Verve Therapeutics Inc (VERV)
6.22
-0.36
(-5.47%)
USD |
NASDAQ |
Apr 25, 16:00
6.235
+0.02
(+0.24%)
After-Hours: 20:00
Verve Therapeutics Cash from Investing (Quarterly): -8.893M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -8.893M |
| September 30, 2023 | -11.83M |
| June 30, 2023 | 33.02M |
| March 31, 2023 | 15.39M |
| December 31, 2022 | -168.31M |
| September 30, 2022 | -55.52M |
| June 30, 2022 | 7.782M |
| March 31, 2022 | 60.09M |
| Date | Value |
|---|---|
| December 31, 2021 | -56.98M |
| September 30, 2021 | -212.32M |
| June 30, 2021 | 18.49M |
| March 31, 2021 | 11.71M |
| December 31, 2020 | 11.89M |
| September 30, 2020 | -2.718M |
| June 30, 2020 | -68.94M |
| March 31, 2020 | 8.639M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-212.32M
Minimum
Sep 2021
60.09M
Maximum
Mar 2022
-26.16M
Average
2.532M
Median
Cash from Investing (Quarterly) Benchmarks
| Acorda Therapeutics Inc | -0.044M |
| Eli Lilly and Co | -2.924B |
| Intellia Therapeutics Inc | 45.94M |
| Beam Therapeutics Inc | 98.10M |
| Gritstone Bio Inc | 38.30M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -40.68M |
| Cash from Financing (Quarterly) | 177.38M |
| Free Cash Flow | -158.83M |
| Free Cash Flow Per Share (Quarterly) | -0.5229 |
| Free Cash Flow to Equity (Quarterly) | -42.86M |
| Free Cash Flow to Firm (Quarterly) | -42.86M |
| Free Cash Flow Yield | -37.89% |